Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) announced that on July 1, 2026, its controlling subsidiary, Jushi Biologics, signed a Collaboration, Option, and License Agreement with AstraZeneca PLC. The partnership focuses on strategic collaboration in the field of novel small interfering RNA candidate drugs, aimed at developing innovative extrahepatic delivery small interfering RNA drug candidates.
According to the terms of the agreement, Jushi Biologics received a $30 million upfront payment from AstraZeneca PLC on August 12, 2026. The actual amount received is subject to a deduction for bank handling fees.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments